Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25031746 | 0.96 | DRD2 (0.55) | DRD2TDP1SIGMAR1MEN1GAA | |
| SCHEMBL16480069 | 0.91 | CACNA1H (0.54) | DRD2TDP1CACNA1HEPHX1 | |
| SCHEMBL25032149 | 0.89 | HRH3 (0.48) | DRD2TDP1SIGMAR1MEN1KMT2A | |
| SCHEMBL24619896 | 0.89 | DRD2 (0.54) | DRD2TDP1SIGMAR1MEN1GAA | |
| SCHEMBL22699069 | 0.89 | DRD2 (0.54) | DRD2TDP1SIGMAR1MEN1GAA | |
| SCHEMBL8254760 | 0.88 | DRD2 (0.64) | DRD2TDP1SIGMAR1MEN1GAA | |
| SCHEMBL6700 | 0.87 | DRD2 (0.53) | DRD2TDP1SIGMAR1MEN1GAA | |
| SCHEMBL24922242 | 0.85 | DRD2 (0.51) | DRD2TDP1SIGMAR1MEN1GAA | |
| SCHEMBL22703621 | 0.85 | DRD2 (0.54) | DRD2TDP1SIGMAR1MEN1GAA | |
| SCHEMBL21815267 | 0.84 | DRD2 (0.50) | DRD2TDP1SIGMAR1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-05 | — | — | US | disclosed |
| US-9675697-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | DRD2 4222/4885TDP1 546/4885SIGMAR1 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.